The primary objective of the project is to design and develop a novel point-of-care assay for rapid detection of three protein biomarkers, namely, neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1) and fatty acid binding protein 1 (FABP1), for rapid diagnosis and prognosis of acute kidney injury (AKI). The incidence of dialysis-requiring AKI, which involves rapid loss of kidney's excretory function, has risen about 10% per year in the United States between 2000 and 2009. During the same time period, the number of deaths associated with dialysis-requiring AKI has more than doubled. In the United States, about 1.2 million patients are diagnosed with AKI and about 0.3 million die of AKI each year. The average length of stay in an ICU is increased by 3.5 days adding about 9 billion dollars in cost. Thus, the measurement of plasma and/or urine biomarker levels is of huge clinical importance. Various proteins such as NGAL, interleukin-18 (IL-18), KIM-1, cystatin C (CysC), and liver fatty acid-binding protein (FABP1) have been extensively studied as potential biomarkers for AKI. For example, during AKI, urinary NGAL levels are increased by several log-orders of magnitude while plasma levels increase 5 to10-fold. It has been recognized that plasma and urine levels of NGAL alone provide early detection and prognosis of patients at risk of developing AKI and support the differential diagnosis of established AKI. Current commercial assays are primarily immune-based and require clinical lab settings to measure protein biomarker concentration in physiological fluids, which not only makes the assay expensive but also results in significant delay. We propose to develop a novel point-of-care assay based on plasmonic nanotransducers and artificial antibodies for the detection of protein biomarkers at physiological and pathological concentrations. Specifically, we will investigate gold nanocages as plasmonic nanotransducers and molecularly imprinted artificial antibodies as recognition elements for selective capture of biomarkers and their quantification by simple hand-held vis-NIR spectrometer. Apart from significantly lowering the cost, the envisioned plasmonic biosensor based on artificial antibodies offers excellent chemical and temporal stability, obviating the need for special storage conditions (e.g., refrigeration, hydration) of and enabling point-of-care biomarker quantification even in resource-limited settings. Once this early, innovative and exploratory research is completed, we will have laid the groundwork and partially developed highly sensitive point-of-care plasmonic biosensor for the detection of protein biomarkers in urine and/or plasma, which enables rapid screening, early detection, diagnosis and prognosis of AKI. The stage would be set for the next steps, of developing plasmonic paper-based biochips for monitoring multiple biomarkers from urine, which enhances the accuracy of diagnosis and prognosis of various pathological conditions.

Public Health Relevance

We propose to develop a novel point-of-care assay for rapid detection of proteins such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1) and fatty acid binding protein 1 (FABP1), potential biomarkers for AKI. The envisioned novel plasmonic biosensor based on artificial antibodies will be a life-saving technology in that it eliminates the significant time lapse associated with current immune-based technologies, which require clinical settings to quantitatively measure protein biomarker levels in physiological fluids (e.g., urine and plasma), thus enabling clinical practitioners to make critica decisions immediately.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21DK100759-02
Application #
9144377
Study Section
Special Emphasis Panel (ZRG1-DKUS-A (56))
Program Officer
Kimmel, Paul
Project Start
2015-09-15
Project End
2017-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
2
Fiscal Year
2016
Total Cost
$205,623
Indirect Cost
$70,788
Name
Washington University
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Wang, Congzhou; Wang, Lu; Tadepalli, Sirimuvva et al. (2018) Ultrarobust Biochips with Metal-Organic Framework Coating for Point-of-Care Diagnosis. ACS Sens 3:342-351
Wang, Congzhou; Tadepalli, Sirimuvva; Luan, Jingyi et al. (2017) Metal-Organic Framework as a Protective Coating for Biodiagnostic Chips. Adv Mater 29:
Wang, Congzhou; Hu, Rong; Morrissey, Jeremiah J et al. (2017) Single Molecule Force Spectroscopy to Compare Natural versus Artificial Antibody-Antigen Interaction. Small 13:
Hu, Rong; Luan, Jingyi; Kharasch, Evan D et al. (2017) Aromatic Functionality of Target Proteins Influences Monomer Selection for Creating Artificial Antibodies on Plasmonic Biosensors. ACS Appl Mater Interfaces 9:145-151
Luan, Jingyi; Liu, Keng-Ku; Tadepalli, Sirimuvva et al. (2016) PEGylated Artificial Antibodies: Plasmonic Biosensors with Improved Selectivity. ACS Appl Mater Interfaces 8:23509-16
Wang, Congzhou; Luan, Jingyi; Tadepalli, Sirimuvva et al. (2016) Silk-Encapsulated Plasmonic Biochips with Enhanced Thermal Stability. ACS Appl Mater Interfaces 8:26493-26500